Currently, cell therapy programmes under development at ECBio are based on UCX® and comprise two different therapeutic areas: cardiovascular disorders, such as peripheral artery disease and myocardial infarction, and immune-related disorders, such as rheumatoid arthritis. All programmes are based on the use of allogeneic UCX® cells in their undifferentiated state.
Technological platform overview and corresponding therapeutic applications currently under development at ECBio (all based on UCX® technology).
The cell therapy areas under the UCX® platform are currently being developed towards application in humans. The first two stages are the in vitro and in vivo proofs-of-concept, looking to demonstrate both safety and efficacy. Relevant animal model studies are being concluded in most areas. Peripheral artery disease and rheumatoid arthritis are initiating clinical trials.